Buy PT-141 10mg

PT-141 (bremelanotide) is a cyclic heptapeptide analog of α-MSH designed with high selectivity for MC4R and MC3R over MC1R, enabling it to produce sexual arousal and facilitate erectile function through central CNS mechanisms without significant melanocyte stimulation or skin tanning. The compound emerged directly from Melanotan II research at the University of Arizona when investigators noted that the spontaneous erectile responses in male subjects during MT-II trials were so robust and reproducible that they warranted development of a targeted analog stripped of the tanning and nausea side effects. PT-141 achieved FDA approval in June 2019 as Vyleesi (bremelanotide injection, 1.75 mg) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — the first pharmacological treatment for female HSDD to receive FDA approval. The MC4R-mediated mechanism of PT-141 in sexual function operates at the level of the hypothalamus and limbic system rather than through peripheral vascular mechanisms. MC4R is expressed at high density in the paraventricular nucleus (PVN) of the hypothalamus, a region that integrates hormonal, emotional, and sensory inputs to regulate sexual motivation, arousal, and the initiation of sexual behavior. Activation of PVN MC4R by PT-141 increases oxytocin release — oxytocin is a neuropeptide critical for social bonding, trust, and sexual engagement — and augments dopamine release in the nucleus accumbens and mesolimbic reward pathway, increasing the motivational salience of sexual stimuli. This hypothalamic mechanism means PT-141 enhances desire and arousal by modulating the CNS circuitry that generates sexual motivation, rather than simply facilitating peripheral erectile mechanics. In males, the spinal cord MC4R signaling activated by PT-141 promotes penile smooth muscle relaxation via nitric oxide synthase activation in the sacral parasympathetic neurons — producing erections through a mechanism that is synergistic with but independent of PDE5. This dual CNS+peripheral mechanism means PT-141 can produce erections in men who are non-responsive to sildenafil and other PDE5 inhibitors, including those with neurogenic ED where the PDE5 pathway is functionally intact but the CNS arousal and spinal cord signal initiation are impaired. Clinical studies demonstrated erections in sildenafil non-responders following PT-141 administration, establishing it as a genuinely alternative mechanism rather than a redundant one. The gender symmetry of PT-141's mechanism — operating through the same MC4R/hypothalamic pathway in both males and females — distinguishes it from PDE5 inhibitors, which have minimal efficacy in female sexual dysfunction because the penile erectile mechanism they target has no female equivalent. In women, PT-141 activates the same PVN oxytocin and mesolimbic dopamine pathways that govern sexual desire and arousal, producing the increased sexual motivation that is the defining pharmacological effect validated in HSDD trials. The FDA approval for HSDD in premenopausal women represents regulatory validation of a CNS-targeted approach to female sexual dysfunction.

The existence of FDA-approved Vyleesi (bremelanotide 1.75 mg/0.3 mL auto-injector) provides an important quality and dosing reference for PT-141 research products. The clinical approval dose of 1.75 mg subcutaneously as needed (maximum once per 24 hours) is well-characterized in terms of safety and efficacy in women. Male studies used doses of 1–5 mg subcutaneously, with 2 mg being the most consistently effective dose in ED trials. Research peptide PT-141 should be verified by mass spectrometry to match the Vyleesi bremelanotide molecular weight (1025.2 g/mol) and the specific cyclic structure that confers its selectivity profile; linear analogs or differently cyclized variants may have different receptor binding profiles. HPLC purity ≥98% is the minimum standard. Because PT-141 has regulatory approval, synthesis quality benchmarks are available: manufacturers supplying pharmaceutical-grade research material can in principle be held to comparable purity standards as the approved drug. Endotoxin testing is important for injectable preparations. The 10 mg vial provides approximately 4–6 injections at the male research dose range (1.75–2.5 mg per session), making it an appropriate format for initial cycle assessment. Timing of administration is critical for desired effect: PT-141 typically requires 45–90 minutes to produce maximal arousal effects, making pre-planning necessary for on-demand use. Taking with an antiemetic (ondansetron 4 mg orally) 30 minutes before administration is the most effective nausea mitigation strategy. The FDA label explicitly warns against use in individuals with cardiovascular disease or uncontrolled hypertension; blood pressure monitoring during initial use sessions is prudent.

PT-141 occupies a pharmacologically unique niche: it is the only approved or well-studied compound that enhances sexual desire and arousal through CNS mechanism rather than peripheral vascular manipulation. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) enhance penile erection by preventing cGMP degradation in penile smooth muscle, directly facilitating the vascular mechanics of erection — but they do not enhance desire, arousal, or subjective sexual motivation. In men with adequate desire but mechanical ED, PDE5 inhibitors are first-line. In men and women with desire/arousal dysfunction — the more common complaint in women and in aging men — PT-141 addresses the problem at its neurobiological origin. Against testosterone supplementation for low sexual desire, PT-141 provides on-demand effect without chronic hormonal alteration or the associated risks (erythrocytosis, prostate concerns, fertility suppression). In clinical practice, the appropriate comparison depends entirely on etiology: desire impairment due to androgen deficiency responds to testosterone; desire impairment with normal androgen levels involves CNS melanocortin pathway changes better addressed by PT-141. Combined use has been proposed for hypogonadal men with both mechanical and motivational components, though systematic combination studies are lacking. For women with HSDD, PT-141 (Vyleesi) is one of only two FDA-approved treatments and is uniquely positioned as the on-demand option.